ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $23,816.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $59.54, for a total transaction of $23,816.00. Following the completion of the sale, the vice president now directly owns 83,478 shares of the company’s stock, valued at $4,970,280.12. The trade was a 0.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Meredith Cook also recently made the following trade(s):

• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $59.99 on Thursday. The stock’s fifty day simple moving average is $56.99 and its 200 day simple moving average is $58.23. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -109.07 and a beta of 0.74. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81.

Analyst Ratings Changes

ANIP has been the subject of several recent analyst reports. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $77.71.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Thrivent Financial for Lutherans lifted its stake in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after buying an additional 299 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in shares of ANI Pharmaceuticals by 3.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after acquiring an additional 300 shares in the last quarter. Exchange Traded Concepts LLC grew its position in ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after purchasing an additional 310 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in ANI Pharmaceuticals by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock valued at $582,000 after purchasing an additional 364 shares during the period. Finally, New York State Teachers Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 1.7% in the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.